Because transplantation for methylmalonic acidaemia prioritizes quality of life over long-term outcomes, justice and utility must be considered.

Equal access is a goal even when patients present with taboo illnesses. But, the date of a patient’s last drink still matters.

Lack of training and lack of knowledge can adversely influence a patient’s clinical outcomes.

If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.

Many devices in current use were marketed before manufacturers were required to demonstrate safety and effectiveness.

Calls to expand palliative care education have been explicit since the 1990s, but palliative care training in surgery remains too narrowly focused on end of life.

Some clinicians offering image-guided procedures have little training in palliative medicine, which is both a clinical and an ethical problem.

Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.

Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"

Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"